Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;331:372 (13 August), doi:10.1136/bmj.331.7513.372
A randomised placebo controlled trial has shown that adding a nightly mesalazine enema improves remission rates in patients with extensive ulcerative colitis who are already being treated with the oral preparation. After eight weeks, nearly 90% of those receiving combined treatment had improved (44% in remission) compared with under 70% of those having placebo enemas (34% in remission). Treatment was safe and well accepted, so should be considered as first line for those with colitis extending beyond the splenic flexure.
Gut
2005;54: 960-5
|
Nearly half of 55 junior doctors surveyed at one hospital could not identify the safe area for insertion of a chest drain, as defined by the British Thoracic Society. Senior house officers were more likely than preregistration house officers to pick the correct area on a photograph, as were those with previous experience of undertaking the task. All those with cardiothoracic surgical experience found the right spot, but only 40% of those with experience in respiratory medicine did so. As doctors in many hospital departments might meet a patient with a large pneumothorax (rim of air > 2cm between chest wall and lung margin), the authors advise that training programmes should make inserting a chest drain a priority.
Postgrad Med J
2005;81: 456-8
New Zealand researchers targeted young mobile phone users who said they wanted to quit smoking. They agreed a quit date about 30 days after randomisation. The intervention groupinitially 852 strongwere bombarded with personalised text messages providing advice, support, and distraction. Half the messages were smoking based and half were distractions involving sports, fashion, travel, and trivia. Five messages were sent for each of the five days before the quit date and throughout the following month. Six weeks later, twice as many in the intervention group had quit compared with controls (who simply received a weekly thnk u txt). Both groups over-reported, but random confirmation by salivary cotinine measurements showed this was equal in the groups. At 26 weeks' follow-up (and despite differential dropouts) people in the intervention group were still more likely to have quit. The authors say the next stop is China, with its 250 million mobile phone users.
Tobacco Control doi: 10.1136/tc.2005.011577
|
Thirty three patients with mild, early Alzheimer's disease drove a monitored vehicle along a one mile stretch of dual carriageway, during which they were asked to verbally identify road signs and restaurants.
The patients performed poorly compared with age matched controls without neurological impairment. They identified fewer landmarks and committed more at-fault safety errors, such as failing to notice a large speed limit sign, suggesting difficulty in task switching between driving and observing. Some Alzheimer patients performed well, so assessing fitness to drive should include controlled cognitive challenges while driving.
J Neurol Neurosurg Psychiatry
2005;76: 764-8
Harvey Marcovitch, BMJ syndication editor
(h.marcovitch{at}btinternet.com)
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses